performed on frozen sections. However, BUdR is a potential carcinogen and must be given intravenously to the patient preoperatively. Fortunately, an analogue antibody to Ki67 has been produced which enables identification of cycling cells in formalin-fixed, paraffin-embedded tissues. This antibody recognizes an antigen known as MIB-1. Today, PCNA, and MIB-1 immunohistochemistry can be performed routinely on paraffin-embedded material ( fig. 1 ). Recent studies, however, have suggested that a certain level of PCNA immunostaining may be artifactual and not truly reflective of cell proliferation. Therefore, MIB-1 has become the favored proliferation marker which correlates well with in vitro BUdR uptake. Cell Proliferation Marker Expression in Pediatric Brain Tumors Most of the literature on cell kinetic analyses generally pertains to adult brain tumors, although some studies have included pediatric tumors. Hoshino et al. [9] showed that the probability of survival among patients with a BUdR-labeling index under 1 % was much higher than in those with indices greater than 5%. Moreover, they reported on a cell kinetic study comparing four medullo-blastomas with malignant gliomas using 3 H-thymidine incorporation [13] . The average labeling index was more than 10%, but the mean survival time was 6 years. In contrast, patients with malignant gliomas that had a labeling index of &gt;5º/o died within 1 year of diagnosis. Therefore, a high labeling index was not necessarily associated with a poor prognosis in patients with medulloblastoma. This discrepancy in survival and labeling index levels can be attributed, no doubt, to the greater sensitivity of medulloblastoma to radiation therapy and chemotherapy. Ito et al. [14] reported on a BUdR-labeling analysis of 50 juvenile pilocytic astrocytomas. They found that the mean BUdR-labeling index was approximately 1%. Their results suggest that most juvenile pilocytic astrocytomas grow slowly as a result of these low BUdR-labeling indices. Some patients in their study had tumors with high labeling indices and some of their tumors recurred. However, in most cases, the clinical course was excellent regardless of the labeling index. Immunohistochemical analyses with Ki-67 have now been performed and reported for large series of human brain tumors including pediatric brain tumors [15] [16] [17] [18] . In most studies, the Ki-67-labeling index, defined as the number of positive staining cells divided by the total number of tumor cells, has ranged from 0 to 50% and has correlated well with the histopathological grade of malignancy of the tumor. In pilocytic astrocytomas, this index was generally low with scores ranging from 0 to 1 %. In primitive neuroectodermal tumors and/or medulloblasto-mas, the index has ranged from 5 to 50%. The mean index Cell Cycle Control in Pediatric Neuro-Oncology PediatrNeurosurg 1997; 26:226-235 227 v 
Mitosis/cytokinesis GO Quiescence Fig. 2 . A proliferating cell passes through an orderly sequence of phases which comprise the cell cycle. Following mitosis, differentiated cells exit the cell cycle after mitosis to enter a state of quiescence called GO. If a cell is destined to continue to proliferate, it enters the first phase of interphase called Gl, which is characterized by a period of cell growth and synthesis of components necessary for DNA synthesis. During this phase the cell is sensitive to conditions in its environment. If these conditions are unfavorable, the cell can arrest in Gl. There is a point, called the restriction point (R), which is the decision-making point for cell cycle progression, and it precedes the onset of the S phase by 1-3 h. The S phase follows Gl and is the period in which chromosomal DNA is replicated. The next phase, called G2, is shorter than Gl and precedes the mitotic phase. During the G2 phase, DNA replication must be completed before the cell enters mitosis. In the mitotic phase, equal amounts of chromosomal material migrate to opposite poles of the cell. The subsequent division of the cytoplasm by cytokinesis results in two identical but separate daughter cells. The fundamental basis of many chemotherapeut-ic agents in use today for children with brain tumors is the blocking of tumor cell division in either a cell cycle phase-specific or nonspecific fashion.
for medulloblastoma is approximately 10%. In a series of 117 pediatric brain and spinal tumors from our center [17] , the mean Ki-67 index was 0.81% in lowgrade astrocytomas, 0.931% in pilocytic astrocytomas, 5.02% in anaplastic astrocytomas, 6.12% in glioblastomas, 2.83% in ependymomas, 6.45% in anaplastic ependymomas, 14.26% in choroid plexus carcinomas, and up to 22% in medulloblastomas. Bodey et al. [18] suggested that the highest indices were found among the poorly differentiated classic medulloblastomas. The inherent problem of regional variability must be considered in the interpretation of Ki-67 indices, especially in tumors with extensive necrosis or in tumors like anaplastic ependymoma which show well-differentiated and poorly differentiated areas. Interestingly, two groups, Schiffer et al. [19] and Iijima and Nakazato [20] , showed that there is an inherent problem of regional variability in medulloblastoma. Light-looking areas (large cell areas) and dark areas (desmoplas-tic and classic areas) may have completely different prolif-erative indices (PCNA and MIB-1 staining). The light areas consistently showed lower staining indices than did the dark areas. It has been suggested that the light areas consist of cells with a more differentiated neuronal lineage with a relatively low proliferation potential. Pollack et al. [21] reported on the relationship between the MIB-1-labeling index and outcome in malignant glio-mas of childhood. The median overall survival was more than 4 years in the low-MIB-1 index group compared with only 16 months in the high index group. Their results suggested the potential utility of the MIB-1-labeling index as a prognostic marker in children with malignant gliomas [21] . Because of the results from the studies listed above, application of these proliferation indices as an adjunct to the diagnosis of brain tumors has become widespread among neuropathologists. The Cell Cycle An understanding of the cell cycle is critical to understanding normal cell proliferation and the altered proliferation observed in various brain tumors, such as human gliomas. A proliferating cell passes through an orderly sequence of phases which comprise the cell cycle ( fig. 2) . Following mitosis, a cell enters interphase. Differentiated cells exit the cell cycle after mitosis to enter a state of quiescence called GO. The proliferating cell, on the other hand, progresses into the first phase of interphase called Gl, which is characterized by a period of cell growth and synthesis of components necessary for DNA synthesis. S phase follows Gl and is the period in which chromosomal DNA is replicated. The next phase, called G2, is shorter than Gl and precedes the mitotic phase. During the G2 phase, DNA replication must be completed before the cell enters mitosis. In the mitotic phase, equal amounts of chromosomal material migrate to opposite poles of the cell. The subsequent division of the cytoplasm by cytokinesis results in two identical but separate daughter cells. The cell cycle phase which is most strategically positioned to control cell proliferation is Gl. During the Gl phase, the critical decision (restriction point) to go on to DNA synthesis and mitosis is made [22] . This restriction point is the decision-making point for cell cycle progression, and it precedes the onset of S phase by 1-3 h. Extra-228 Pediatr Neurosurg 1997;26:226-235 Tsugu/Dirks/Jung/Kurimoto/Jay/ Murakami/Rutka cellular factors such as growth factors may help to determine whether a cell in GO phase will enter the cell cycle and proliferate (GO to Gl), or whether a proliferating cell continues to proliferate (Gl to S) or exits the cell cycle and becomes quiescent (Gl to GO). In short, before this checkpoint, growth factors are required to progress through the first phases of the cell cycle. On the other hand, once a cell has passed the restriction point it must undergo mitosis regardless of whether or not growth factor signals are present. Therefore, the molecular controls at the restriction point are the focus of intensive study. The decision to progress through the restriction point is determined by the activity of proteins which form the molecular cell cycle machinery, cyclins, CDKs and their inhibitors.
Cyclins and CDKs Act as Positive Growth Regulators
The major positive growth regulators of the cell cycle are a group of related proteins, the cyclins. Cyclins are a group of structurally similar proteins which share homol-ogy in a conserved 100-amino acid domain known as the cyclin box [23] . Cyclins are the positive regulatory sub-units of a class of related protein kinases, called CDKs. These cyclin-CDK complexes are the regulators of the major cell cycle transitions ( fig. 3 ). When cells emerge from the GO phase and enter Gl, the expression of D-and E-type cyclins is induced. At the onset of the S phase, cyclin A is first detected followed by cyclin B during the interval between the S phase and mitosis (G2) followed by rapid degradation at the end of the M phase. There are two main families of cyclins, the mitotic cyclins and Gl cyclins. Mitotic cyclins consist of cyclin B and cyclin A. Cyclin A also has a second role in the S phase of the cell cycle. The Gl cyclins are cyclins C, D, and E. Cyclin can interact with different CDKs. The CDKs are believed to phosphorylate key substrates which are required to facilitate the passage of the cell through each phase of the cell cycle. Substrates of CDKs can be structural proteins, which act as the actual effectors of a cell cycle phase transition, or regulatory molecules [24] [25] [26] . The best characterized targets of D-type cyclin kinase activity are the pRB family proteins. During the Gl phase, phosphorylation of pRB, by sequential activation of D-type cyclins and CDK4/CDK6 and cyclin E/CDK2 may be the single most important event in the cell cycle as it initiates the S phase [27] [28] [29] [30] . CDKIs Act as Negative Growth Regulators Cell proliferation consists of a balance between the expression of genes which stimulate growth and genes Fig. 3 . Cyclins are the positive regulatory subunits of a class of related protein kinases, called cyclin-dependent kinases (CDKs). These cyclin-CDK complexes are the regulators of the major cell cycle transitions. The CDKs are believed to phosphorylate key substrates which are required to facilitate the passage of the cell through each phase of the cell cycle. Substrates of CDKs can be structural proteins, which act as the actual effectors of a cell cycle phase transition, or regulatory molecules. Cyclin-CDK complexes have kinase activity, but if the complexes associate with CDK inhibitors (CDKIs), the complex is no longer active. which inhibit growth. Recently it has been shown that a family of CDKIs plays a major role in the negative regulation of cyclin-CDK activity [31, 32] . These Gl cyclin inhibitors are involved in the arrest in Gl of cells in response to antiproliferative signals. Therefore, all CDKIs are candidate tumor-suppressor genes. The CDKIs can be subdivided into two families, those which inhibit multiple cyclin-CDK complexes, such as p2lCIPl, p27KIPl, p57KIP2, and those which inhibit the Gl cyclin-CDK4/6 complexes, pl6INK4A, pl5INK4B, pl8INK4C, and pl9INK4D ( fig. 4) . p2lCIPl plays an important role in p53-mediated Glinduced cell cycle arrest in response to DNA damage [33] . p27KIPl is thought to mediate cell cycle arrest caused by cell contact inhibition or transforming growth factor ß treatment [34, 35] . In addition CDKIs may be involved in such diverse processes as terminal differentiation, cellular senescence, repairment to DNA damage, and induction of apoptosis [36] . Loss of expression of a CDKI may have disastrous consequences for the cell. For example, loss of the pl6INK4A has been linked to many human cancers. A simplified schema which enables visualization of the cyclins, CDKs, and CDKIs in practical terms in cell cycle control is shown in figure 5 . CDKIs can be subdivided into two families: those which inhibit multiple cyclin-CDK complexes, such as p2lCIPl, p27KIPl, p57KIP2, and those which inhibit the Gl cyclin-CDK4/6 complexes, pl6INK4A, pl5INK4B, pl8INK4C, and pl9INK4D. p2lCIPl plays an important role in p53-mediated Glinduced cell cycle arrest in response to DNA damage.
p27KIPl is thought to mediate cell cycle arrest caused by cell contact inhibition or transforming growth factor ß (TGF-ß) treatment. DNA damage | TGF-ß p53 cell contact ↓ 1 p2l¤P¡ ¢∑IKIPI p57ifƒƒ·2 cyclinD CDK4/CDK6 v \φtK4A j&gt;l¦INK4B cycl⅛AcyclinB CDK1 CDK1 p2l«W p27*f« p57KIP2 p2l≈W p27*'W p57raº2 CELL CYCLE CONTROL ^_ Cyclins Cycl¡n dependent kinase inhibitors p21, p27, p57 p15, p16, p18, p19 w (A, B1, D1, D2, D3, E) ‡ Cyclin dependent kinases (CDK1, CDK2, CDK4, COK6) Ret&gt;noblastoma protein(pRb) CyÇlin activating kinases ( CAKs) Fig. 5 . Cell cycle control can be made analogous to the control of an automobile in that the drivers or accelerators of the cell cycle are the cyclins and cyclin-dependent kinases (CDKs), whereas the brakes are the CDK inhibitors (CDKIs), suchaspl5, l6, p2l andp27. Strategies to prevent tumor cell proliferation can be thought of in terms of decreasing the expression levels of the drivers (analogous to taking one's foot off the accelerator), or increasing the expression of the inhibitors (putting one's foot on the brakes). Indeed, several molecular biological strategies are being used today to accomplish these results with expression vector systems and anti-sense technology. Dysregulation of the Cell Cycle in Brain Tumors Proliferation of normal cells is controlled by multiple growth-regulatory pathways that act to ensure proper growth regulation. It is generally thought that cancer cells ignore many growth-regulatory signals due to mutation in genes (genetic 'hits') that control either the growth-promoting or growth-inhibitory pathways. Therefore, transformation of glial cells into malignant astrocytomas involves significant dysfunction of the cell cycle-control machinery. There have been a number of recent studies which have shown alterations in cell cycle gene expression in human astrocytic tumors. Most of the studies on cell cycle gene expression in neurooncology generally pertain to adult brain tumors, although some studies include an analysis of pediatric tumors. pl6INK4A (MTS1/CDKN2) For human malignant gliomas, two genetic loci are particularly interesting: MST1 and CCND1 [37] . CCND1 encodes cyclin Dl while the MST1 locus controls expression of two independent but closely related tumor-suppressor genes, pl6INK4A and pl5INK4B. Interestingly, human cyclin D1 was cloned in a yeast complementation asssay from a Ul 18MG glioblastoma cDNA library [38] . pl6INK4A is an important component of a cell cycle regulatory pathway involving cyclin Dl, CDK4, and pRB. pl6INK4A inhibits the kinase activity of the cyclin Dl-CDK4 complex by binding to CDK4 and preventing its association with its catalytic subunit cyclin Dl. Cyclin Dl-CDK4 phosphorylates pRB during the Gl phase of the cell cycle to inhibit its growth-restraining activity. As a result, phosphorylated pRB is no longer able to bind to 230 PediatrNeurosurg 1997;26:226-235 Tsugu/Dirks/Jung/Kurimoto/Jay/ Murakami/Rutka pl6W¿MΛ F¡g. 6. pl6INK4A is an important component of a cell cycle regulatory pathway involving cyclin Dl, CDK4, and retinoblas-toma protein (pRB). pl6INK4A inhibits the kinase activity of the cyclin Dl-CDK4 complex by binding to CDK4 and preventing its association with its catalytic subunit cyclin Dl. Cyclin Dl-CDK4 phosphorylates pRB during the Gl phase of the cell cycle to inhibit its growth-restraining activity. As a result, phosphorylated pRB is no longer able to bind to and prevent the activity of the E2F transcription factors. Phosphorylation of pRB releases E2F transcription factors to enter into the S phase. This event is believed to be an important checkpoint regulating the transition from Gl into the S phase during cell cycle progression. cycl⅛Dl/CDK4 phosphorylate and prevent the activity of the E2F transcription factors. This event is believed to be an important checkpoint regulating the transition from Gl into the S phase during cell cycle progression. Gene transfer of a full-length pl6INK4A cDNA into U25 IMG or U87MG astrocyto-ma cell lines that did not express endogeneous p 16INK4A resulted in marked growth suppression [39] . Infection of the adenovirus vector carrying the full-length pl6INK4A in U25 IMG or U87MG cell lines also arrested in the G0-Gl phases of the cell cycle and modified the transformed phenotype of cells including the ability to form colonies in soft agar [40] . It is clear, however, that deletion may not be the only mechanism for pl6INK4A inactivation, as lack of expression of protein has been found in a significant percentage of grade-IΠ and grade-IV malignant as-trocytic tumors that retain wild-type pl6INK4A [41, 42] . CpG island methylation of the pl6INK4A promoter region may be responsible for decreased protein expression in the setting of an unaltered pl6INK4A DNA sequence. This methylationassociated inactivation of pl6INK4A expression may mechanistically result from structural changes in the chromatin containing the pl6INK4A locus [43, 44] . Interestingly, pl6INK4A ho-mozygous deletion frequently involves deletion of the closely linked pl5INK4B gene [45] [46] [47] [48] [49] . Derangements in both the positive cell cycle regulators, cyclin Dl and CDK4, and the negative regulators, pl6INK4A and pl5INK4B, have been found previously in malignant astrocytomas [41] [42] [43] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] . Interestingly, in glioma cells that do not have pl6INK4A homozygous deletions, CDK4 overexpression and amplification are common, suggesting that a further mechanism for uncontrolled glioma cell growth is the overriding of a negative regulator by a positive regulator [41, 42, 48, 50, 55] . Indeed, it has recently been reported that loss of expression of pl6INK4A or pRB, and overexpression of CDK4 occur in a mutually exclusive fashion in the majority of glioma cell lines or malignant glial tumors [42, 49, 50] . These results suggest that the pl6INK4A-cyclin D1/ CDK4-pRB axis is a critical growth regulatory pathway in malignant gliomas ( fig. 6 ). In this context, it is conceivable that an alteration in any member of this pathway may play an important role in glial oncogenesis. pl6INK4A point mutations are only rarely observed in malignant astrocytic tumors that retain a pl6INK4A allele [46] . There is a correlation between the frequency of homozygous deletion and malignancy, since low-grade astrocytomas do not have homozygous pl6INK4A deletion [46, 56] . The majority of these studies have detected a p 16INK4A or p 15INK4B mutation or loss of expression in the astrocytic tumors, while these molecular changes have not been detected in ependymomas or neuroectoder-mal tumors [45, 63] . In addition, loss of pl6INK4A protein without pl6INK4A gene deletion was reported in pituitary tumors [64] .
Cell Cycle Control in Pediatric Neuro-Oncology PediatrNeurosurg 1997;26:226-235 231 With regard to pediatric brain tumors, most investigators have found rare instances of pl6INK4A homozygous deletions and no point mutations in meduUoblastomas [45, 65, 66] . Petronio et al. [60] detected a single case of pl6INK4A homozygous deletion among 20 primitive neuroectodermal tumors. In addition, pl6INK4A homozygous deletions or CDK4 amplification were restricted to adult cases of gliomas, since neither was seen in pediatric high-grade gliomas [60] . Interestingly, Sure et al. [66] reported that loss of pl6INK4A expression was observed in 61 % of pediatric glioblastomas using immunohistochemistry which is within the range (40-60%) reported for homozygous deletions of the pl6INK4A gene and loss of p 16INK4A expression by other means in adult glioblastomas [41, 42, 45, 55] . Recently, overexpression of cyclin B1 and p 16INK4 expression has been described in the SF-188 pediatric glioblastoma cell line [67] . p2lCIPl and Its Transcriptional Activator, p53 p2lCIPl plays an important role in p53-mediated Gl-induced cell cycle arrest in response to DNA damage. For example, in response to DNA damage by drugs or radiation, internal signals lead to the increased expression of p53, which causes Gl cell cycle arrest mediated by activation of p2lCIPl [33, 68, 69] . We have recently shown that p2lCIPl expression is diminished in several astrocytic tumor cell lines with wild-type p53 status [67] . Infection of the p53-deficient astrocytoma cell line, U 373 MG with a replication-defective adenoviral vector containing p21WAF1/CIP1 led to G1 cell cycle arrest and inhibition of accumulation of cells with aneuploidy [70] . In addition, an alteration in the malignant phenotype of cells was evidenced by the loss of anchorage-independent growth in soft agar and the failure to induce tumorigenesis in both peripheral and intracranial xenograft models [70] . Another group has shown that infection of a pCL-based retroviral vector carrying p2lCIPl in rat glioblastoma cells showed a 91 % reduction in colony-forming efficiency and a 66% reduction in growth rate [71] . In addition, intracranial implantation of these infected cells showed complete disappearance of the p2lCIPl-infected cells by day 10 and long-term survival compared to controls [71] . Interestingly, the ectopic expression of cyclin Dl in asynchronously growing cells (human glioma and rodent fibroblast cell lines) was accompanied by increased levels of the p53 protein and p2lCIPl. Despite the induction of these cell cycle-inhibitory proteins, cyclin Dl-associated CDK kinase remained activated and the cells grew essentially like that of the parental cell lines [72] . Jung et al. [73] performed a study which demonstrated altered expression of p21CIP1 in astrocytic tumor cells. In glioblastoma multiforme, there was marked elevation of p21 CIP 1 in samples harboring either wild-type or mutant p53. p2lCIPl expression was not elevated in samples harboring mutant type p53 in anaplastic astrocytomas. In addition, the level of p21 expression was very low in normal brain tissue [73] . Tsumanuma et al. [74] reported on the mutation of the p2lCIPl gene in 28 brain tumors. Since this mutation was detected in only two tumors (one astrocytic tumor and one medulloblastoma), they concluded that mutation of the p2lCIPl gene was infrequent in brain tumors [74] .
There have been few studies describing the expression of p53 expression in gliomas of childhood [66, [75] [76] [77] [78] [79] . Mutations of the p53 gene in particular have been reported to be uncommon in childhood gliomas, a finding which contrasts with their frequent detection in adult gliomas. Litofsky et al. [76] did not find any p53 mutations in 12 anaplastic astrocytomas and 2 glioblastomas and concluded that p53 mutations are not of importance in the development of pediatric astrocytomas. On the other hand, Schiffer et al. [78] reported that p53 mutations were found in 2 of 8 glioblastomas and 1 of 9 anaplastic astrocytomas, whereas no mutations were found in 11 pilocytic astrocytomas. Sure et al. [66] also reported that mutations in the p53 gene were identified in 25% of glioblastomas. Indeed, Pollack et al. [79] reported on the relationship between mutations of the p53 gene and overexpression of p53 and prognosis. There was a significant association between p5 3 gene mutations and/or overexpression of p53 and poor prognosis. Sidransky et al. [80] showed that progression from low-to high-grade glioma in adults was associated with a clonal expansion of cells that had previously acquired a mutation in the p53 gene. In our center, we have observed consistent p53 immunopositivity in choroid plexus carcinomas, and a lack of positivity in most papillomas. With respect to meduUoblastomas, cytogenic analyses have shown a number of nonrandom chromosomal alterations, including deletions on chromosome 17 [81, 82] . Loss of l7p, the chromosomal arm on which the p53 gene is located, has been found in approximately one third of meduUoblastomas. However, direct analysis of the p53 gene for mutations in medulloblastoma has revealed a low incidence equaling approximately 10% [83] [84] [85] [86] . This suggests that other tumor-suppressor genes important in the pathogenesis of medulloblastoma may exist on chromosome l7p. Cogen and McDonald [87] have been investigating one candidate gene within the active-BCR-related locus which is on the distal portion of chromosome l7p.
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Pediatr Neurosurg 1997;26:226-235 Tsugu/Dirks/Jung/Kurimoto/Jay/ Murakami/Rutka Other CDK Inhibitors When the p27KIPl gene was transfected with the human astrocytoma cell line, U373MG, using an adeno-viral vector system, there was cell cycle arrest in Gl and a marked decrease in the accumulation of aneuploid cells [88] . We have demonstrated that the p57KIP2-deficient human astrocytoma cell line, U343MG-A, is rapidly blocked in Gl following induced expression of p57KIP2 [89] . Studies in Transgenic Mice Recently, molecular techniques have advanced remarkably so that the effect of deregulated overexpression or the absence of expression of a gene can be studied in the whole organism, such as a transgenic mouse. A number of important tumor-suppressor genes have been 'knocked out' in mice, and the phenotype of the mice has supported the candidate gene's tumor-suppressive function. Homo-zygous knockout of p53 leads to spontaneous development of many different tumors, although none in the brain [90] . Double RB and p53 knockout mice develop endocrine tumors, including pituitary tumors and pineoblastomas [90, 91] . pl6INK4A transgenic mice are susceptible to multiple tumors, although none in the brain [92] . p2lCIPl knockout has very little phenotypic effect without predisposition to tumor formation [93] . Homozy-gous p27KIPl knockout results in a dramatic phenotype, with much larger sized mice with multiorgan hyperplasia and spontaneous development of intermediate lobe tumors of the pituitary gland [94] [95] [96] . p57KIP2 transgenic mice have delayed differentiation without tumor formation [97, 98] . Conclusion The field of molecular biology has advanced remarkably, as has our understanding of the process of cell proliferation. A number of cell cycle-regulatory proteins play an important role in the regulation of cell proliferation. Cell proliferation consists of a balance between expression of genes which stimulate growth and genes which inhibit growth, such as Rb or p53 or CDKIs. We may now be in a position to design new biotherapeutic strategies to reduce the proliferation of brain tumor cells by blocking specific cell cycle proteins or by enhancing the function of CDKIs. For example, we have recently shown that transfection of U343 astrocytoma cells with a pi6 retrovirus in addition to treatment with retinoic acid leads to signals which cause full differentiation of these malignant astrocytoma cells [99] . In the future, one can envision applying such combination therapy with cell cycle inhibitors and differentiation agents to patients with malignant astrocytomas. Finally, with future advancements in targeting cells with gene therapy and with advances in molecular diagnosis, we believe that much of our knowledge about the cell cycle will be translated into new and effective therapies for children harboring intracranial neoplasms.
